Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. With the latest financial year loss of US$78m and a trailing-twelve-month loss of US$50m, the US$1.0b market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Aurinia Pharmaceuticals' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. According to the 7 industry analysts covering Aurinia Pharmaceuticals, the consensus is that breakeven is near. They expect the company to post a final loss in 2023, before turning a profit of US$7.
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisBusiness Wire
- Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment [Seeking Alpha]Seeking Alpha
- Aurinia Pharmaceuticals: This Recovery Can Continue [Seeking Alpha]Seeking Alpha
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.MarketBeat
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare ConferenceBusiness Wire
AUPH
Earnings
- 8/1/24 - In-Line
AUPH
Sec Filings
- 9/23/24 - Form 3
- 9/20/24 - Form 4
- 9/12/24 - Form SC
- AUPH's page on the SEC website